Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

103.88 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

70 71 Next >

Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown ↗

April 23, 2024

Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams.

Via Benzinga

Topics Intellectual Property

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

April 22, 2024

From BioNTech SE

Via GlobeNewswire

Assessing BioNTech: Insights From 11 Financial Analysts ↗

April 17, 2024

Via Benzinga

Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert ↗

April 12, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For BioNTech ↗

March 21, 2024

Via Benzinga

Earnings Outlook For BioNTech ↗

March 19, 2024

Via Benzinga

Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024? ↗

April 09, 2024

These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.

Via InvestorPlace

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

April 07, 2024

From BioNTech SE

Via GlobeNewswire

CureVac, GS Partner Release Data On Influenza Vaccine Study ↗

April 04, 2024

CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A...

Via Benzinga

The 3 Best Bargain Stocks to Buy in Q2 2024 ↗

March 31, 2024

For those who don’t want to chase what everyone else is acquiring, these are intriguing ideas for best bargain stocks to buy.

Via InvestorPlace

3 Biotech Stocks to Buy for the Next Bull Run: March 2024 ↗

March 26, 2024

These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.

Via InvestorPlace

BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript ↗

March 20, 2024

BNTX earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 20, 2024

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and...

Via Benzinga

BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials ↗

March 20, 2024

BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine.

Via Benzinga

Stocks Quietly Higher As Central Bank Wraps Up Meeting ↗

March 20, 2024

Stocks are cautiously higher ahead of the conclusion of the central bank's policy meeting.

Via Talk Markets

Topics Economy

BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q4 2023 ↗

March 20, 2024

BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

BioNTech Tumbles As Fourth-Quarter Sales Dive 65% And Miss Forecasts ↗

March 20, 2024

BioNTech also reported plummeting earnings that missed forecasts and issued light 2024 guidance.

Via Investor's Business Daily

Why Is BioNTech Stock Trading Lower On Wednesday? ↗

March 20, 2024

BioNTech reported Q4 2023 earnings below expectations, with EPS at €1.90 vs. €9.26 last year. Sales were €1.479 billion, missing consensus. Guidance for 2024 anticipates revenues of €2.5-€3.1 billion,...

Via Benzinga

US Stock Futures Stall As Traders Await Fed Chair Powell's Decision; Analyst Sees S&P 500 Showing 'Signs Of Near-Term Top' ↗

March 20, 2024

Investors remain cautious ahead of the Federal Reserve‘s interest rate decision, with stock futures on Wednesday hinting at a lower opening.

Via Benzinga

Topics Economy Stocks

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

March 20, 2024

From BioNTech SE

Via GlobeNewswire

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

March 20, 2024

From BioNTech SE

Via GlobeNewswire

Earnings Scheduled For March 20, 2024 ↗

March 20, 2024

Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.

Via Benzinga

Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗

March 13, 2024

One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.

Via InvestorPlace

BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

March 12, 2024

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

March 12, 2024

WHY: NEW YORK, NY - (NewMediaWire) - March 12, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...

Via TheNewswire.com

Topics Lawsuit

BNTX DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

March 11, 2024

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

BNTX DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

March 11, 2024

WHY: NEW YORK, NY - (NewMediaWire) - March 11, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...

Via TheNewswire.com

Topics Lawsuit

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE (BNTX)

March 11, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

BIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE

March 11, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

March 11, 2024

From BioNTech SE

Via GlobeNewswire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

70 71 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.